Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.88 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | CES1 | P23141 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8991893 | 0.98 | TDP1 (0.84) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL43476 | 0.94 | TDP1 (1.00) | TDP1SRD5A2MAPK1POLBMEN1 | |
| Terephthalic Acid SCHEMBL28023943 | 0.94 | TDP1 (1.00) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL11648887 | 0.92 | TDP1 (0.81) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL1566327 | 0.91 | TDP1 (0.95) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL10439552 | 0.91 | TDP1 (0.95) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL17332065 | 0.91 | TDP1 (0.95) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL11773857 | 0.91 | TDP1 (0.95) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL17332086 | 0.91 | TDP1 (0.95) | TDP1SRD5A2MAPK1POLBMEN1 | |
| 4-Nitrobenzoic Acid SCHEMBL11331124 | 0.91 | TDP1 (0.95) | TDP1SRD5A2MAPK1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306669-A | Benzimidazole diamine and polybenzimidazole imide as well as preparation methods and application thereof | 中广核研究院有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | claimed |
| US-5412044-A | Nitro group terminated mesogenic epoxy resin adducts | THE DOW CHEMICAL COMPANY (US) | 1995-05-02 | — | — | US | claimed |
| JP-2169582-A | — | — | None | — | — | JP | disclosed |
| CN-119306669-A | Benzimidazole diamine and polybenzimidazole imide as well as preparation methods and application thereof | 中广核研究院有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118496135-B | Thiourea compound or pharmaceutically acceptable salt thereof and application thereof as immunosuppressant | 中国海洋大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118496135-A | Thiourea compound or pharmaceutically acceptable salt thereof and application thereof as immunosuppressant | 中国海洋大学 | 2024-08-16 | — | — | CN | disclosed |
| EP-3389781-B1 | INHIBITORS OF TNF SUPERFAMILY COSTIMULATORY INTERACTIONS AND METHODS FOR USES OF THE SAME | UNIV MIAMI (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10562848-B2 | Inhibitors of TNF superfamily costimulatory interactions and methods for uses of the same | UNIVERSITY OF MIAMI (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180370909-A1 | INHIBITORS OF TNF SUPERFAMILY COSTIMULATORY INTERACTIONS AND METHODS FOR USES OF THE SAME | UNIVERSITY OF MIAMI (US) | 2018-12-27 | — | — | US | disclosed |
| EP-3389781-A1 | INHIBITORS OF TNF SUPERFAMILY COSTIMULATORY INTERACTIONS AND METHODS FOR USES OF THE SAME | University of Miami (US) | 2018-10-24 | — | — | EP | disclosed |
| US-5464912-A | Adduct with rodlike mesogenic moiety, adduct made by reacting polyepoxide with nitro/so/ compound having epoxy-reactive hydrogen; conversion of hydroxyl product to ether, ester, halide, urethane, ketone, alkane; reducing nitro/so/ to amine | THE DOW CHEMICAL COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| US-5412044-A | Nitro group terminated mesogenic epoxy resin adducts | THE DOW CHEMICAL COMPANY (US) | 1995-05-02 | — | — | US | disclosed |
| US-5346648-A | Antiferroelectric liquid crystal compound and liquid crystal composition containing the same | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1994-09-13 | — | — | US | disclosed |
| US-5344898-A | Curable composition with stilbene groups and molecular orientation | THE DOW CHEMICAL COMPANY (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0592269-A1 | Antiferroelectric liquid crystal compound and liquid crystal composition containing the same | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1994-04-13 | — | — | EP | disclosed |
| US-5298575-A | Consists of at least one compound having more than one vicinal epoxide group and at least one amine terminated adduct containing one or more mesogenic moities | THE DOW CHEMICAL COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| JP-H02169582-A | NOVEL DIAMINE COMPOUND AND PRODUCTION THEREOF | MITSUI TOATSU CHEM INC | 1990-06-29 | — | — | JP | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
| US-4011173-A | MODIFIED NEMATIC MIXTURES WITH POSITIVE DIELECTRIC ANISOTROPY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370909-A1 | INHIBITORS OF TNF SUPERFAMILY COSTIMULATORY INTERACTIONS AND METHODS FOR USES OF THE SAME | CD40, TNFRSF9, TNFRSF1A | TDP1 2916/4885SRD5A2 3491/4885MAPK1 393/4885 |
| US-10562848-B2 | Inhibitors of TNF superfamily costimulatory interactions and methods for uses of the same | CD40, TNFRSF9, TNFRSF1A | TDP1 2916/4885SRD5A2 3491/4885MAPK1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.